Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vivos Therapeutics Q2 2024 GAAP EPS $(0.60) Beats $(0.92) Estimate, Sales $4.05M Beat $3.60M Estimate

Author: Benzinga Newsdesk | August 14, 2024 04:15pm
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.92) by 34.78 percent. The company reported quarterly sales of $4.05 million which beat the analyst consensus estimate of $3.60 million by 12.61 percent. This is a 19.41 percent increase over sales of $3.40 million the same period last year.

Posted In: VVOS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist